Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus

Endocrinol Metab 2022;37:170–4;

Finerenone induced a 13% risk reduction in MACE (a composite of death from CV causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for heart failure) regardless of prior glycaemia. There was no difference in finerenone-derived MACE benefits whether patients were on baseline SGLT2i or GLP-1RA or not.

This analysis of RCTs aimed to determine the cardioprotective effect of finerenone according to prior treatment with newer antidiabetics and glycaemic status.